// App-Quantinova.ai

543 : Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab

Researchers

Presenter

  • Elaine M. Pinheiro

Principal Investigators

  • Marlene Hinton

  • Ruban Mangadu

  • Mingmei Cai

  • Uyen Phan

  • Michael Nebozhyn

  • Heather Hirsch

  • Andrey Loboda

  • Sarah Javaid

  • Yaolin Wang

  • Venkataraman Sriram

  • Joseph H. Phillips

  • Terri McClanahan

  • Brian Long

Medical Centers

  • Merck & Co., Inc., Kenilworth, NJ

  • SUNY Stony Brook, Stony Brook, NY

  • University of Madras, Palo Alto, CA.

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved